Replimune stock.
Replimune Group, Inc. (REPL) has been beaten down lately with too much selling pressure. While the stock has lost 14.6% over the past four weeks, there is light at the end of the tunnel as it is ...
Replimune Group, Inc., headquartered in Woburn, MA, was founded in 2015 with the mission to transform cancer treatment by pioneering the development of novel tumor-directed oncolytic immunotherapies. Replimune’s proprietary RPx platform is based on a potent HSV-1 backbone with payloads added to maximize immunogenic cell death …Christopher Sarchi REPL stock SEC Form 4 insiders trading. Christopher has made over 1 trades of the Replimune Inc stock since 2023, according to the Form 4 filled with the SEC. Most recently Christopher sold 5,255 units of REPL stock worth $57,385 on 16 November 2023.. The largest trade Christopher's ever made was selling 5,255 …Replimune Group, Inc., headquartered in Woburn, MA, was founded in 2015 with the mission to transform cancer treatment by pioneering the development of novel tumor-directed oncolytic immunotherapies. Replimune’s proprietary RPx platform is based on a potent HSV-1 backbone with payloads added to maximize immunogenic cell death …Replimune Group Inc. Watch list Set a price target alert After Hours Last Updated: Nov 29, 2023 4:02 p.m. EST Delayed quote $ 11.32 0.00 0.00% After Hours Volume: 16.73K Advanced Charting Volume:...
We would like to show you a description here but the site won’t allow us.Replimune overview. Replimune, a subsidiary of Replimune Group Inc, is a pharmaceutical company that develops oncolytic immunotherapies for the treatment of cancer. The company’s pipeline products include RP1 used for the treatment of oncolytic immunotherapy backbone, and RP2 and RP3 for expressing anti-CTLA-4 and co …
Stock USD 19.28 0.44 2.23% Given the investment horizon of 90 days and your slightly conservative level of risk, our recommendation regarding Replimune Group is 'Hold'
Discover historical prices for REPL stock on Yahoo Finance. View daily, weekly or monthly format back to when Replimune Group, Inc. stock was issued. Replimune Group, Inc. is a clinical-stage biotechnology company engaged in the business of oncolytic immunotherapy to treat cancer patients. The Company is advancing a pipeline of tumor-directed oncolytic immunotherapies derived from its RPx platform to fill unmet need across cancer types.Replimune remains on track to initiate its Phase 2 development program with RP2/3 in the first half of 2023. As previously announced, this program is intended to include Phase 2 clinical trials in ...15 Okt 2020 ... Replimune stock rallied on leaked RP1 and RP2 clinical trial data. Its cash position enables it to invest more in clinical studies.About Replimune Replimune Group, Inc., headquartered in Woburn, MA, was founded in 2015 with the mission to transform cancer treatment by pioneering the development of novel tumor-directed oncolytic immunotherapies. Replimune’s proprietary RPx platform is based on a potent HSV-1 backbone with payloads added to maximize immunogenic cell death ...
Replimune | Stock Quote & Chart Investors & Media Overview Events and Presentations Press Releases Corporate Governance Financials & Filings Stock Information Publications Email Alerts Investor Contact Select Page Stock Quote & Chart Stock Quote & Chart Historical Price Analyst Coverage Change Volume Today's Open Previous Close Today's High
Earnings for Replimune Group are expected to decrease in the coming year, from ($3.53) to ($3.93) per share. Replimune Group has not formally confirmed its next earnings publication date, but the company's estimated earnings date is Thursday, February 8th, 2024 based off prior year's report dates.
According to Accountingbase.com, common stock is neither an asset nor a liability; it is considered equity. Equity is basically considered to mathematically be the difference between the total assets and total liabilities of a company.From the period between 2010 and 2023, Replimune, Working Capital regression line of its data series had standard deviation of 201,967,139 and standard deviation of 201,967,139. Replimune Operating Expenses is quite stable at the moment as compared to the past year. The company's current value of Operating Expenses is estimated at 191.06 Million.Get the latest Replimune Group Inc. (REPL) stock price, news, buy or sell recommendation, and investing advice from Wall Street professionals.Replimune's RPx platform, featuring RP1, RP2, and RP3, showcases a comprehensive and innovative approach to cancer treatment. Find out why REPL stock is a Buy.Replimune Group : The very small 0.44% REPL stake saw a ~18% increase last quarter at prices between ~$17 and ~$28. The stock is now at ~$19. The stock is now at ~$19. Note: they have a ~10% ...If you’re just getting started, tracking investments might seem like a mystery. Thankfully, modern tools and technology make it easier than ever to figure out how to manage your stock portfolio and to track it. This quick guide gives you ti...Investing in the stock market takes a lot of courage, a lot of research, and a lot of wisdom. One of the most important steps is understanding how a stock has performed in the past. Of course, the past is not a guarantee of future performan...
Complete Replimune Group Inc. stock information by Barron's. View real-time REPL stock price and news, along with industry-best analysis.... Stock REPL REPLIMUNE GROUP, INC. PDF Report. PDF Report : Replimune Group, Inc. Consensus Replimune Group, Inc. Equities. REPL. US76029N1063. Real-time Estimate ...Replimune believes that data with both RP2 and RP3 in CRC will allow the comparative efficacy of RP2 and RP3 to be evaluated in a particularly difficult to treat patient population. Investor event and webcast information. Replimune will host a virtual investor event today, Wednesday, December 7, 2022 at 8:00 a.m. ET.18 Sep 2023 ... at Replimune and Gilead also shared how they're accelerating ... Veeva (VEEV stock) Exceptional Business! SaaS Growth Stock for Life Sciences ...Replimune Group Inc [REPL] stock prices are up 4.74% to $11.71 at the moment. An important factor to consider is whether the stock is rising or falling in short …May 18, 2023 · Replimune Group, Inc., headquartered in Woburn, MA, was founded in 2015 with the mission to transform cancer treatment by pioneering the development of novel tumor-directed oncolytic immunotherapies. Replimune’s proprietary RPx platform is based on a potent HSV-1 backbone with payloads added to maximize immunogenic cell death and the ...
Contact Email: [email protected]. Contact Phone Number: +1 (781) 222 9570. Replimune’s investigational products and their uses are investigational, have not been proven to be safe and have not been approved by the United States Food and Drug Administration (FDA), the European Medicines Agency (EMA) or any other regulatory …Replimune’s tumor-directed oncolytic immunotherapies have the potential to redefine the cancer treatment paradigm. Replimune’s approach brings together multiple mechanisms of action to destroy the tumor, ignite an anti-cancer response, and generate long-lived immune activity. The ultimate aim is to improve outcomes for patients with cancer.
Replimune Group Stock Performance. Shares of REPL stock opened at $11.71 on Monday. The company has a market cap of $691.58 million, a price-to-earnings ratio of -3.80 and a beta of 1.46. The stock has a 50 day simple moving average of $13.43 and a 200-day simple moving average of $18.08.WOBURN, Mass., Nov. 03, 2023 (GLOBE NEWSWIRE) -- Replimune Group, Inc. (NASDAQ: REPL), a clinical stage biotechnology company pioneering the development of a novel portfolio of oncolytic immunotherapies, today announced updated interim results from ARTACUS, a Phase 1/2 clinical trial evaluating RP1 monotherapy for the treatment of skin cancers in patients who have had solid organ or ...The shares of common stock and the pre-funded warrants described above are being offered by Replimune pursuant to its shelf registration statement on Form S-3, including a base prospectus, that ...Woburn, MA. 51 to 200 Employees. Type: Company - Public (REPL) Founded in 2015. Revenue: Unknown / Non-Applicable. Biotech & Pharmaceuticals. Competitors: Unknown. Replimune is a biotechnology firm that develops oncolytic immuno-gene therapies to treat cancer. The powerful Immulytic™ platform combines multiple mechanisms to deliver …In conclusion, Replimune Group Inc’s stock performance has been buoyed by positive price forecasts from 10 analysts, with a median target price of $50.00. Despite reporting negative earnings per share for the current quarter, investors remain optimistic about the company’s long-term potential.Replimune is advancing a pipeline of tumor-directed oncolytic immunotherapies derived from its RPx platform to fill unmet need across cancer types. RPx therapies are engineered using a proprietary HSV-1 strain and immune activating transgenes to maximize T cell stimulation and systemic immune activation. RP1 is designed to treat more immune ...Replimune | 9,469 followers on LinkedIn. Replimune's mission is to revolutionize cancer treatment with therapies designed to activate a powerful and durable full-body anti-tumor response.Feb 24, 2023 · Replimune Group, Inc. (REPL) has been beaten down lately with too much selling pressure. While the stock has lost 14.6% over the past four weeks, there is light at the end of the tunnel as it is ... Replimune Group, Inc., headquartered in Woburn, MA, was founded in 2015 with the mission to transform cancer treatment by pioneering the development of novel tumor-directed oncolytic immunotherapies. Replimune’s proprietary RPx platform is based on a potent HSV-1 backbone with payloads added to maximize immunogenic cell death …Also, insider Konstantinos Xynos sold 7,313 shares of Replimune Group stock in a transaction that occurred on Thursday, November 16th. The stock was sold at …
Nov 21, 2023 · HC Wainwright dropped their price target on shares of Replimune Group from $50.00 to $48.00 and set a “buy” rating on the stock in a research report on Monday, November 13th. Six investment analysts have rated the stock with a buy rating, According to MarketBeat, Replimune Group has a consensus rating of “Buy” and an average price ...
WOBURN, Mass. , Aug. 01, 2023 (GLOBE NEWSWIRE) -- Replimune Group, Inc. (NASDAQ: REPL), a clinical stage biotechnology company pioneering the development of a novel portfolio of tumor-directed oncolytic immunotherapies, today announced that members from the Replimune management team will present. July 31, 2023.
Complete Replimune Group Inc. stock information by Barron's. View real-time REPL stock price and news, along with industry-best analysis.Nov 5, 2023 · To begin my analysis, Replimune's Q2 earnings revealed an upswing in expenditures, with R&D costs climbing 37% to $40.4M and SG&A expenses up 33% to $15.2M, culminating in a heightened operating ... Track Replimune Group Inc (REPL) Stock Price, Quote, latest community messages, chart, news and other stock related information. Share your ideas and get valuable insights from the community of like minded traders and investorsReplimune Group, Inc., headquartered in Woburn, MA, was founded in 2015 with the mission to transform cancer treatment by pioneering the development of novel tumor-directed oncolytic immunotherapies. Replimune’s proprietary RPx platform is based on a potent HSV-1 backbone with payloads added to maximize immunogenic cell death …Replimune Group, Inc. Common Stock (REPL) Stock Quotes - Nasdaq offers stock quotes & market activity data for US and global markets.BOSTON, Dec. 07, 2022 (GLOBE NEWSWIRE) -- Replimune Group, Inc. (Nasdaq: REPL), a clinical stage biotechnology company pioneering the development of a novel class of tumor-directed oncolytic immunotherapies, today announced a proposed public offering of $125 million of shares of its common stock and pre-funded warrants to purchase shares of common stock.BMO Capital Markets raised the price target on Replimune Group Inc (NASDAQ: REPL) to $40 from $30 on a bullish view into upcoming data readouts for lead asset RP1 in melanoma and cutaneous ...Replimune Group, Inc. is a clinical-stage biotechnology company. It engages in the business of developing oncolytic immunotherapies for the treatment of cancer. The company was founded by Philip Astley-Sparke, Colin A. Love, and Robert Coffin in March 2015 and is headquartered in Woburn, MA. REPL - Replimune Group Inc - Stock screener for ...
Shares of Replimune Group, Inc. (NASDAQ:REPL – Get Free Report) have been given an average rating of “Buy” by the six research firms that are presently covering the firm, MarketBeat.com reports.Six equities research analysts have rated the stock with a buy recommendation. The average 12 month price target among brokerages that have …Replimune will never request any financial information, funds, or passport details as part of the recruitment process. We employ a formal process that includes an interview with a member of our HR team. This is required and the only way to secure an employment offer from Replimune.Dec 1, 2023 · 6 brokers have issued 12-month price objectives for Replimune Group's shares. Their REPL share price targets range from $34.00 to $70.00. On average, they anticipate the company's share price to reach $51.33 in the next year. This suggests a possible upside of 353.5% from the stock's current price. Instagram:https://instagram. cheap computer tablesvgsh yieldrobert half international stockadvisor client td According to Accountingbase.com, common stock is neither an asset nor a liability; it is considered equity. Equity is basically considered to mathematically be the difference between the total assets and total liabilities of a company. xlv holdingsbrokers for day trading We would like to show you a description here but the site won’t allow us. live day trading simulator Replimune Group Stock (NASDAQ: REPL) stock price, news, charts, stock research, profile.Find out all the key statistics for Replimune Group, Inc. (REPL), including valuation measures, fiscal year financial statistics, trading record, share statistics and more. ... Stock Price History ...Replimune Group stock price forecast: $52; Market Cap: 686.26M, Enterprise value: 781.76M, P/E: -5.9, PEG ratio: 0.20, EPS: -3.1, Revenue: N/A, ...